A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.

Also called NCT06897202

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 133 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06897202
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06897202. Randomized; double masking; primary purpose treatment. Start 2025-03-14 (actual); primary completion 2025-12-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
Acronym
VESPER-2
Condition
Obesity in Diabetes
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
MET097 Injection
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct06897202
Content hash
b4b82d27f2c92dc8e612998a17a45e93afd63bc338187d2575c3f0ed3622e1d9